Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

  • End date
    Aug 31, 2023
  • participants needed
  • sponsor
    Gilead Sciences
Updated on 31 July 2021
hodgkin's disease
flow cytometry
cell transplantation
gilbert's syndrome
neutrophil count
follicular lymphoma
diffuse large b-cell lymphoma
b-cell lymphoma
marginal zone lymphoma
large b-cell lymphoma
indolent lymphoma
refractory non-hodgkin's lymphoma
non-hodgkin's lymphoma refractory


The primary objective of this study is to determine the safety and tolerability of GS-0189 (formerly FSI-189) as monotherapy and in combination with rituximab in participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).


The study will consist of 5 parts: 1) an initial Monotherapy Dose Escalation (MDE) part, 2) a Combination Dose Escalation (CDE) part, 3) a Pharmacokinetic (PK) Evaluation part, 4) an Alternate Schedule Evaluation (ASE) part and 5) a diffuse large B-cell lymphoma (DLBCL) Expansion part.

Condition Lymphoma, Lymphoma, Non-Hodgkin's Lymphoma, non-hodgkin's lymphoma (nhl)
Treatment Rituximab, FSI-189, GS-0189
Clinical Study IdentifierNCT04502706
SponsorGilead Sciences
Last Modified on31 July 2021


Yes No Not Sure

Inclusion Criteria

DLBCL, follicular lymphoma (FL), or marginal zone lymphoma (MZL) expressing CD20 by immunohistochemistry (IHC) or flow cytometry, relapsed/refractory (R/R) to at least 2 prior lines of therapy. Prior autologous hematopoietic cell transplantation and individuals with transformed lymphomas are permitted. Individuals must be at least 3 months out from prior autologous hematopoietic cell transplantation. Individuals with indolent lymphomas must be candidates for systemic treatment in the judgment of the treating physician
In the DLBCL Expansion part: Individuals must have de novo or transformed DLBCL expressing CD20 by IHC or flow cytometry, that is relapsed or refractory to at least 2 prior lines of therapy. Prior autologous hematopoietic cell transplantation and individuals with transformed lymphomas are permitted
Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
For the DLBCL expansion cohort, disease must be measurable for response per Lugano criteria. For all other cohorts, disease must be measurable or assessable for response per Lugano criteria
Exhibit acceptable hematopoietic, liver, renal, and coagulation function as assessed by laboratory tests

Exclusion Criteria

Previous anticancer therapy including chemotherapy, hormonal therapy, and investigational agents within 3 weeks or at least 4 half-lives (up to a maximum of 4 weeks), whichever is longer, prior to first dose of study drug
Individuals with active brain metastases (Individuals with stable treated central nervous system (CNS) lesions who are off corticosteroid therapy for at least 3 weeks are not considered active
Individuals with Burkitt's lymphoma
Prior treatment with a chimeric antigen receptor (CAR) T-cell therapy
Prior allogeneic stem cell transplant
Rituximab-containing cohorts only: Receipt of live/attenuated vaccines within 30 days of rituximab dosing
Known active or chronic hepatitis B or C infection or human immunodeficiency virus
Prior treatment with CD47 or signal regulatory protein alpha (SIRP)-targeting agents
Hypersensitivity to the active substance, to murine proteins, or to any of the other excipients of rituximab
Significant medical diseases or conditions, as assessed by the Investigator and Sponsor, that would substantially increase the risk:benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction within the last 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections, severely immunocompromised state, and congestive heart failure New York Heart Association Classes II to IV
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note